Cilostazol, which increases the intracellular cAMP levels, inhibited the lipopolysaccharide (LPS)-induced in TLR4 by repressing the transcriptional activity of PU.1 in macrophages from patients with RA. This evidence concerns the gene TLR4 and rheumatoid arthritis.